Steroid therapy and antiviral treatment in SARS-CoV-2 pneumonia: clinical contexts and indicationsSARS-CoV-2 폐렴에서 스테로이드 요법 및 항바이러스 치료: 임상적 맥락 및 적응증Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] 28-day mortality Antiviral treatment benefit Clinical improvement clinical trial complications Corticosteroids Critically ill Critically ill patient critically ill patients decrease Dexamethasone Disease progression drug Effectiveness Fluid management group Health Organization higher risk include indication measure mechanical ventilation Meta-analysis Mortality oxygen Oxygen therapy Patient patients with COVID-19 per day performed Placebo RECOVERY trial reduction in Remdesivir requiring supplemental oxygen routine care SARS-CoV-2 Standard of care steroid therapy subgroup analysis supplemental oxygen supportive care systemic corticosteroid systemic corticosteroids Trial WHO with COVID-19 World Health Organization [DOI] 10.37201/req/s01.13.2022 PMC 바로가기 [Article Type] Review
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trialRandomized Controlled Trial Published on 2022-04-012022-10-04 Journal: CJEM [Category] 임상, [키워드] COVID days alive Dexamethasone Effect randomized trial Support with COVID-19 [DOI] 10.1007/s43678-022-00293-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort studyObservational Study Published on 2022-04-012022-10-04 Journal: International Journal of Environmental Research an [Category] 임상, 치료법, [키워드] adjusted odds ratio administration Care chronic neurological disease clinical clinical decision Clinical practice cohort study Corticosteroid Corticosteroids COVID-19 Critical care Dementia demographics Dexamethasone discrepancy evaluate hospital Hydrocortisone identify Illness severity implementation independent Intervention ISARIC ISRCTN less likelihood Medical Research Council Methylprednisolone Older Patient patients with COVID-19 Prednisolone pregnant women Primary outcome Rate receive RECOVERY trial reduce mortality Registered significantly supplementary oxygen treated Treatment WHO [DOI] 10.1016/S2589-7500(22)00018-8 PMC 바로가기 [Article Type] Observational Study
C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19COVID-19로 입원한 환자의 초기 토실리주맙 및 덱사메타손 처방에 대한 C 반응성 단백질 차단Article Published on 2022-03-282022-09-12 Journal: Scientific Reports [Category] SARS, 바이오마커, 임상, 진단, 치료법, 치료제, [키워드] 30-day mortality rate Admission age Analysis Anti-inflammatory therapy C-reactive protein C-reactive protein (CRP CRP cut-off defined Dexamethasone evaluated help hospital hospitalized patient independent predictor Infection inflammatory activity intensive care Interaction IQR males median Mortality Multivariate analysis outcome Patient performed Primary outcome receiving reduction in reduction in mortality SARS-CoV-2 stratified Tocilizumab variable viral replication with COVID-19 [DOI] 10.1038/s41598-022-08882-x PMC 바로가기 [Article Type] Article
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study groupResearch article Published on 2022-03-252022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 95% CI adverse event Alliance analysed Arm ARMS assigned assistance Bayesian approach clinical trial Clinique confidence interval COVID-19 CPS CrI cumulative death Dexamethasone Efficacy and safety finding fixed dose funding hazard ratio Health incidence intent-to-treat Interpretation investigated Mechanical mechanical ventilation mechanical ventilation support moderate-to-severe COVID-19 moderate-to-severe COVID-19 pneumonia Mortality occurred Occurrence organization oxygen oxygen supply Paris Patient Primary outcome progression provided randomised randomization Randomized randomized clinical trial Randomly receive reduce repeated Roche significantly study group TCZ Tocilizumab Tocilizumab+Dexamethasone Treatment Ventilation ventilatory support WHO [DOI] 10.1016/j.eclinm.2022.101362 [Article Type] Research article
Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression Research Published on 2022-03-182022-10-05 Journal: Signal Transduction and Targeted Therapy [Category] SARS, 바이오마커, 변종, 신약개발, 임상, 치료법, [키워드] addition approved C-reactive protein clinically Cohort consolidation control group COVID-19 COVID-19 progression D-dimer determine Dexamethasone downregulating effective drug effort evaluate expression fibrinogen ground-glass opacity inhibitor lymphocyte parameters Patient promote pulmonary lesions reduced SARS-CoV-2 sequence therapeutic effect Treatment upregulating Volume [DOI] 10.1038/s41392-022-00952-w [Article Type] Research
Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients중증 COVID-19 환자를 위한 메틸프레드니솔론 요법의 중증도 바이오마커 및 면역학적 특징의 동역학Article Published on 2022-03-082022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, [키워드] “core signature” cytokines. Admission albumin baseline baseline level Biomarker Biomarkers C-reactive protein characterized Clinical characteristics Clinical efficacy clinical outcomes Clinical treatment Cluster correlated Course COVID-19 CRP CXCL10 cytokine cytokine release cytokine release storm Cytokines D-dimer death defined demographics Dexamethasone dimer discharge elevated evaluate FIVE groups Hospital stay IFN-γ IL-6 immune disorder immune disorders immunological IMPROVE involved Kinetics longitudinal MCP-3 mechanism Methylprednisolone multiplex occurred Patient performed receiving remained response severe COVID-19 severe COVID-19 patient severe COVID-19 patients severity significantly supportive therapy Systems biology therapy Treatment two group two groups upregulated [DOI] 10.3389/fimmu.2022.758946 PMC 바로가기 [Article Type] Article
Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19Article Published on 2022-03-042022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] 95% CI 95% confidence interval Admission age calculate changes in clinical Clinical outcome collected Comorbidity coronavirus disease COVID-19 Dexamethasone diagnosed Effect Effectiveness evaluate force information initial body Laboratory Laboratory tests linear Male sex Mild mixed-effects model moderate Moderate COVID-19 multivariate logistic regression not significantly different obesity Odds ratio Older oxygen oxygen supplementation Oxygen therapy Patient percentage Pneumonia Probability reduced regdanvimab Remdesivir retrospective SARS-CoV-2 supplemental oxygen symptom severity score temperature therapeutic options therapy vaccination was used [DOI] 10.3390/jcm11051412 PMC 바로가기 [Article Type] Article
Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of PakistanResearch article Published on 2022-03-012022-10-05 Journal: Exploratory Research in Clinical and Social Pharmacy [Category] 신약개발, 치료제, [키워드] addition Administered Antibiotics Anticoagulant antithrombotic therapy Clinical characteristics Clinical severity Cohort concerning conducted Corticosteroid Corticosteroids COVID-19 COVID-19 severity described Dexamethasone died discharged District enrolled evaluate finding heparin hospitalized patient medication medications Mild mild illness moderate multicenter Pakistan Patient patients patients hospitalized pattern Prevalence provided Repurposed drug retrospective SARS-CoV-2 steroid stratified systemic corticosteroid therapeutic option Treatment with COVID-19 [DOI] 10.1016/j.rcsop.2021.100101 [Article Type] Research article
Clinical outcomes of corticosteroids for COVID-19 patients at the National Center for Global Health and Medicine during the first wave of infectionsResearch article Published on 2022-03-012022-10-05 Journal: Respiratory investigation [Category] SARS, 임상, [키워드] acute respiratory syndrome Admission both groups caused center Characteristics clinical Clinical course Clinical efficacy collected data condition coronavirus Coronavirus disease 2019 Corticosteroid corticosteroid therapy Corticosteroids COVID-19 COVID-19 patient Critically ill patient Dexamethasone diagnosed with COVID-19 examined Fever First wave global health hospital ill patients Infection infections Japan medical record Medicine mortality rate no difference no statistical difference outbreak outcome Patient patients with COVID-19 polymerase chain Primary outcome reduced Result SARS-CoV 2 seven-category ordinal scale severely ill patient treated Treatment two group with COVID-19 [DOI] 10.1016/j.resinv.2021.11.001 [Article Type] Research article